H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on EKSO BIONICS (EKSO – Research Report) today and set a price target of $1.20. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.48.
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.4% and a 31.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, Corcept Therapeutics Inc, and IntelGenx Technologies.
EKSO BIONICS has an analyst consensus of Strong Buy, with a price target consensus of $1.70.
The company has a one-year high of $2.55 and a one-year low of $0.48. Currently, EKSO BIONICS has an average volume of 501.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ekso Bionics Holdings, Inc. engages in the design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following business segments: EksoHealth, EksoWorks, and Other.